New drug combo could change First-Line myeloma treatment

This study tests a new drug, linvoseltamab, combined with standard treatments (bortezomib and lenalidomide) in people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. Researchers want to see if this new combination works better than the current standard therapy (daratumumab, bortezomib, lenalidomide, and dexamethasone), and whether it might allow some patients to skip the stem cell transplant. About 1,570 participants will be enrolled to compare safety and effectiveness.